^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MUC1 expression + EGFR expression

    i
    Other names: MUC1, ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM, Mucin 1, cell surface associated, Cancer antigen 15-3, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956; 4582
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    6d
    EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer. (PubMed, Front Oncol)
    Single-cell RNA, bulk RNA and IHC data demonstrated the high expression levels and co-expression patterns of EGFR and MUC1 in tumors but not normal tissues. Therefore, it is a promising TAA combination for therapeutic targeting which could enhance on-tumor efficacy while reducing off-tumor toxicity.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MUC1 (Mucin 1)
    |
    EGFR expression • MUC1 expression • MUC1 expression + EGFR expression
    10ms
    MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma. (PubMed, Ann Med)
    The mRNA-seq showed that knocking down MUC1 affected the gene expression, DEGs mainly enriched in NF-κB and MAPK signalling pathway. MUC1 was highly expressed in A549/TAX cells, and MUC1-EGFR crosstalk with IL-6 may be due to the activation of NF-κB and MAPK pathways, which promote the enrichment of CSCs and lead to paclitaxel resistance.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • MUC1 (Mucin 1) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • NANOG (Nanog Homeobox)
    |
    MUC1 expression • MUC1 expression + EGFR expression • IL6 expression • POU5F1 expression
    |
    paclitaxel
    over1year
    M1231 in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=23, Completed, EMD Serono Research & Development Institute, Inc. | Active, not recruiting --> Completed | N=84 --> 23 | Trial completion date: Mar 2024 --> Jun 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability) • MUC1 (Mucin 1)
    |
    MSI-H/dMMR • EGFR expression • MUC1 expression • MUC1 expression + EGFR expression
    |
    M1231